Ceva Biomune Kicks off $7 Million R&D Facility Renovation
Jul 27, 2012
Ceva Biomune, a world leader in animal health vaccines, hosted a kick-off event on Friday, July 20, 2012, for the renovation of its R&D facility. Currently, R&D operates out of 2,200 square feet of lab space. The renovation will give the team 18,000 square feet of BSL-2 (bio safety level 2) laboratory space and 15,000 square feet of office space. Thirty of Ceva’s R&D professionals will work out of leased space in the Venture Accelerator on the Kansas Bioscience Park campus for the one-year duration of the renovation. CRB was awarded the design-build project.
Ceva operates in nearly 150,000 square feet of office, production, research and development, and warehouse space on a campus of six buildings at its U.S. headquarters in Lenexa, Kan. In May 2011, Ceva completed an $18 million expansion of its Biomune poultry vaccine production plant on the same campus. With about 230 employees, the fast growing company added 50 new positions in the last 18 months and anticipates adding between 25 – 100 in the next 18 months.
The ceremony included the signing of a structural beam by attending dignitaries and team members that will be installed in the renovated R&D Facility. Brief speaking presentations were given by Gov. Sam Brownback; Lenexa Mayor Mike Boehm, Ceva Biomune CEO Daryl Pint, and Vice President, Global Biology Research & Development, Steve Chu.